Alan Yu

Dr. Yu received his medical degree from the University of Cambridge, England and completed his internship and residency in Internal Medicine, and clinical and research fellowships in Nephrology at the Brigham and Women's Hospital, Harvard Medical School. He was on faculty at Harvard and USC, before moving to KU in 2011 to lead the Division of Nephrology and the Kidney Institute.

Dr. Yu also serves as the Director of Mentoring and Career Development for the Kansas Institute of Precision Medicine, and as Director of the Clinical Research Core for the NIH-funded Kansas PKD Research and Translation Core Center.

Dr. Yu is an elected member of the American Society of Clinical Investigation, a Fellow of the American College of Physicians.

Education and Training

• BA, Univ. of Cambridge
• MBChB, Univ. of Cambridge
• Residency, Internal Medicine, Brigham and Women's Hospital, Boston, MA
• Clinical Fellowship, Nephrology, Brigham and Women's Hospital, Boston, MA

Licensure, Accreditations & Certifications

• Internal Medicine, American Board of Internal Medicine
• Nephrology, American Board of Internal Medicine

Professional Affiliations

• American Society for Clinical Investigation, Institutional Representative, 2019 - 2019
• American College of Physicians, Fellow, 2015 - Present
• American Society for Clinical Investigation, Member, 2010 - Present

Research

Overview

Dr. Yu's primary research interests are in kidney physiology, epithelial cell biology, and polycystic kidney disease (PKD). The focus of his laboratory is on the role of tight junctions in the regulation of paracellular epithelial permeability. He conducts clinical and translational research to develop new prognostic biomarkers and therapies for PKD. Dr. Yu serves as the principal investigator for CRISP, the longest running cohort study of PKD.

Current Research and Grants

• Role of claudin-2 in calcium homeostasis and kidney stone disease, NIH, PI
• The Kansas Institute for Precision Medicine, NIH
• Kansas PKD Research and Translation Core Center, NIH
• Development of 2-deoxy-D-glucose for the treatment of polycystic kidney disease, Ospedale San Raffaele/ Department of Defense Technology and Therapeutic Award, Other

Publications

• Curry, J., N, Saurette, M, Askari, M, Pei, L, Filla, M., B, Beggs, M., R, Rowe, P., S, Fields, T, Sommer, A., J, Tanikawa, C, Kamatani, Y, Evan, A., P, Totonchi, M, Alexander, R., T, Matsuda, K, Yu, A., S. 2020. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease.. The Journal of clinical investigation, 130 (4), 1948-1960
• Pei, L, Solis, G, Nguyen, M., T, Kamat, N, Magenheimer, L, Zhuo, M, Li , J, Curry, J, McDonough, A., A, Fields, Timothy., A, Welch, W., J, Yu, Alan., Shiu Leun. 2016. Paracellular epithelial sodium transport maximizes energy efficiency in the kidney.. The Journal of clinical investigation, 126 (7), 2509-18
• Yu ASL, Shen, C, Landsittel, D., P, Grantham, J., J, Cook, L., T, Torres, V., E, Chapman, A., B, Bae, K., T, Mrug, M, Harris, P., C, Rahbari-Oskoui, F., F, Shi, T, Bennett, W., M. 2019. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.. Kidney international, 95 (5), 1253-1261
• Yu ASL, Shen, C, Landsittel, D., P, Harris, Penelope , Torres, V., E, Mrug, M, Bae, K., T, Grantham, J., J, Rahbari-Oskoui, F., F, Flessner, M., F, Bennett, W., M, Chapman, A., B. 2018. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.. Kidney international, 93 (3), 691-699